Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031

  1. Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031  Markets Insider

    2. Full coverage